Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Acquisitions & Divestments: 2019-2024

Historic Change in Acquisitions & Divestments for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Dec 2024 value amounting to $288.8 million.

  • Arcutis Biotherapeutics' Change in Acquisitions & Divestments fell 52.22% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.7 million, marking a year-over-year decrease of 20.11%. This contributed to the annual value of $288.8 million for FY2024, which is 28.96% down from last year.
  • Arcutis Biotherapeutics' Change in Acquisitions & Divestments amounted to $288.8 million in FY2024, which was down 28.96% from $406.5 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year Change in Acquisitions & Divestments high stood at $406.5 million for FY2023, and its period low was $97.6 million during FY2020.
  • For the 3-year period, Arcutis Biotherapeutics' Change in Acquisitions & Divestments averaged around $348.9 million, with its median value being $351.5 million (2022).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 180.46% in 2020, then fell by 28.96% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Change in Acquisitions & Divestments (Yearly) stood at $97.6 million in 2020, then skyrocketed by 122.90% to $217.6 million in 2021, then skyrocketed by 61.56% to $351.5 million in 2022, then grew by 15.66% to $406.5 million in 2023, then declined by 28.96% to $288.8 million in 2024.